{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:23:10Z","timestamp":1719620590288},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gesundheitswesen"],"published-print":{"date-parts":[[2023,4]]},"abstract":"Zusammenfassung<\/jats:title>\n Hintergrund Hodenkrebs tritt v.\u2009a. bei jungen M\u00e4nnern\n zwischen 25 und 45 Jahren auf und ist die h\u00e4ufigste Krebserkrankung in\n diesem Alter. M\u00f6gliche Hodenkrebsfr\u00fcherkennungsma\u00dfnahmen\n bei asymptomatischen M\u00e4nnern ab 16 Jahren, wie die \u00e4rztliche\n Tast- und Ultraschalluntersuchung (TUS) bzw. die Tasteigenuntersuchung (TEU)\n k\u00f6nnten Todesf\u00e4lle und aggressive Sp\u00e4ttherapien\n vermeiden. Deshalb wurde untersucht, ob diese Ma\u00dfnahmen einen\n Zusatznutzen im Vergleich zur gegenw\u00e4rtigen Situation sowie relevante\n ethische, rechtliche, soziale und organisatorische Aspekte aufweisen.<\/jats:p>\n Methoden Die Methodik dieses Reviews folgt den \u201eAllgemeine[n]\n Methoden Version 5.0\u201c des IQWiG. Zus\u00e4tzlich wurde zur\n Absch\u00e4tzung der theoretisch m\u00f6glichen Nutzen- und\n Schadenspotenziale eines Screenings eine erg\u00e4nzende Darstellung zur\n Nutzenbewertung anhand ver\u00f6ffentlichter Daten aus Tumorregistern und\n Daten zu pr\u00e4diktiven Werten aus Diagnosestudien herangezogen.<\/jats:p>\n Ergebnisse Es wurden keine Interventionsstudien identifiziert, deshalb\n k\u00f6nnen keine evidenzbasierten Aussagen zu einem zus\u00e4tzlichen\n Nutzen oder Schaden der untersuchten Fr\u00fcherkennungsma\u00dfnahmen\n getroffen werden. Epidemiologischen Daten zeigen, dass pro 100\u2009000\n j\u00e4hrlich am Screening teilnehmenden M\u00e4nnern maximal 1,2\n fortgeschrittene Tumoren und 0,4 Todesf\u00e4lle vermeidbar w\u00e4ren.\n Schadensberechnungen ergeben, dass bei der TUS von 100\u2009000\n M\u00e4nnern mit 1 bis 22 unn\u00f6tigen Hodenfreilegungen oder\n -entfernungen zu rechnen ist, bei der TEU w\u00e4ren es 2 F\u00e4lle.\n Diese Angaben zum m\u00f6glichen Schaden des Screenings sind jedoch mit\n gro\u00dfer Unsicherheit behaftet.<\/jats:p>\n Schlussfolgerungen Es liegen keine Interventionsstudien vor, die\n nachweisen k\u00f6nnten, dass der Nutzen eines Hodenkrebsscreenings bei\n M\u00e4nnern ab 16 Jahren den Schaden \u00fcberwiegt. Der maximal\n m\u00f6gliche Zusatznutzen ist gering und Entdeckungs- und Heilungschancen\n sind auch ohne Screening gut. Derzeit kann ein Hodenkrebsscreening nicht\n empfohlen werden.<\/jats:p>","DOI":"10.1055\/a-1658-0057","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:12:22Z","timestamp":1638835942000},"page":"234-241","source":"Crossref","is-referenced-by-count":0,"title":["Hodenkrebsscreening bei M\u00e4nnern ab 16 Jahren: IQWiG\n ThemenCheck Health Technology Assessment-Bericht zu medizinischen,\n \u00f6konomischen, sozialen, ethischen, rechtlichen und organisatorischen\n Aspekten"],"prefix":"10.1055","volume":"85","author":[{"given":"Petra","family":"Schnell-Inderst","sequence":"additional","affiliation":[{"name":"Dept. of Public Health, Health Services Research and Health Technology\n Assessment, UMIT \u2013 University for Health Sciences, Medical Informatics\n and Technology, Hall i.T, \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Laschkolnig","sequence":"additional","affiliation":[{"name":"Gesundheit \u00d6sterreich GmbH, Wien,\n \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Marckmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Ethik, Geschichte und Theorie der Medizin,\n Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen,\n Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Antony","sequence":"additional","affiliation":[{"name":"Gesundheit \u00d6sterreich GmbH, Wien,\n \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"M\u00fchlberger","sequence":"additional","affiliation":[{"name":"Dept. of Public Health, Health Services Research and Health Technology\n Assessment, UMIT \u2013 University for Health Sciences, Medical Informatics\n and Technology, Hall i.T, \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"ref2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital\n Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"H Moch","year":"2016","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/his.13102","article-title":"The World Health Organization 2016 classification of testicular germ cell\n tumours: a review and update from the International Society of Urological\n Pathology Testis Consultation Panel","volume":"70","author":"S R Williamson","year":"2017","journal-title":"Histopathology"},{"key":"ref4","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of\n Tumours of the Urinary System and Male Genital Organs","author":"World Health Organization","year":"2004"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"vi125","DOI":"10.1093\/annonc\/mdt304","article-title":"Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for\n diagnosis, treatment and follow-up","volume":"24","author":"J Oldenburg","year":"2013","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00345-004-0398-8","article-title":"Clinical epidemiology of testicular germ cell tumors","volume":"22","author":"K P Dieckmann","year":"2004","journal-title":"World J Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1016\/j.urology.2011.02.030","article-title":"Management of low-stage nonseminomatous germ cell tumors of testis:\n SIU\/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009","volume":"78","author":"A J Stephenson","year":"2011","journal-title":"Urology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","article-title":"Guidelines on Testicular Cancer: 2015 Update","volume":"68","author":"P Albers","year":"2015","journal-title":"Eur Urol"},{"key":"ref11","first-page":"w14640","article-title":"Baseline characteristics and patterns of care in testicular cancer patients:\n first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG\n TCCS)","volume":"148","author":"C Rothermundt","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejca.2017.07.015","article-title":"Quality analysis of population-based information on cancer stage at diagnosis\n across Europe, with presentation of stage-specific cancer survival estimates: A\n EUROCARE-5 study","volume":"84","author":"P Minicozzi","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000055323","article-title":"Three-year results of the first educational and early detection program for\n testicular cancer in Hungary","volume":"60","author":"L Geczi","year":"2001","journal-title":"Oncology"},{"key":"ref18","volume-title":"Principles and practice of screening for disease. In, WHO Public health\n papers","author":"JM G Wilson","year":"1968"},{"key":"ref20","volume-title":"Screening. Durchf\u00fchrung und Nutzen von Vorsorgeuntersuchungen","author":"A Raffle","year":"2009"},{"key":"ref21","first-page":"CD007853","article-title":"Screening for testicular cancer","volume":"(2)","author":"D Ilic","journal-title":"Cochrane Database Syst Rev 2011 Feb 16"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-153-6-201009210-00007","article-title":"Screening for testicular cancer: an evidence review for the U.S. Preventive\n Services Task Force","volume":"153","author":"K Lin","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-154-7-201104050-00006","article-title":"Screening for testicular cancer: U.S. Preventive Services Task Force\n reaffirmation recommendation statement","volume":"154","author":"U.S. Preventive Services Task Force\n (USPSTF)","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref24","first-page":"30","article-title":"Screening for testicular and ovarian cancers","volume":"22","author":"M Sladden","year":"1998","journal-title":"Cancer Forum"},{"key":"ref25","volume-title":"Final Evidence Review for Testicular Cancer: Screening","author":"U.S. Preventive Services Task Force\n (USPSTF)","year":"2014"}],"container-title":["Das Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1658-0057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T23:44:10Z","timestamp":1719618250000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1658-0057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":17,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1658-0057","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0941-3790","1439-4421"],"issn-type":[{"value":"0941-3790","type":"print"},{"value":"1439-4421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]}}}